Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Midostaurin cost effective for FLT3-mutated AML

    • 1 Accesses

    This is a preview of subscription content, log in to check access.

    Notes

    1. 1.

      Midostaurin

    Reference

    1. Tremblay G, et al. Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France. European Journal of Health Economics : 22 Jan 2020. Available from: URL: https://doi.org/10.1007/s10198-019-01149-9

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Midostaurin cost effective for FLT3-mutated AML. PharmacoEcon Outcomes News 846, 18 (2020). https://doi.org/10.1007/s40274-020-6557-3

    Download citation